Drug Combination Details
| General Information of the Combination (ID: C76353) | |||||
|---|---|---|---|---|---|
| Name | Deguelin NP Info | + | AG1478 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Metastatic lymph node neoplasm
[ICD-11: 2D60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HSC-4 | CVCL_1289 | Tongue squamous cell carcinoma | Homo sapiens | ||
| Ca9-22 | CVCL_1102 | Gingival squamous cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma. | |||||
